2016
Boston, USADaejeon, Korea
101
(Ph.D. 30)
78.5 million USD
CNS targeted RNAi delivery system
(Neurodegenerative disease)
ISO 9001/13485GMP Facility
Korea Venture Company
Last Updated: March, 2023